LAWRENCE, Mass., Aug. 12, 2014 /PRNewswire/ -- NxStage
Medical, Inc. (NASDAQ: NXTM), a leading manufacturer of
innovative dialysis products, announced today that Allan J. Collins, M.D., a recognized worldwide
leader in the field of nephrology, will join the Company as Senior
Medical Advisor and head the Company's Medical Advisory
Board.
Dr. Collins is a Professor of Medicine at the University of
Minnesota. He is the Director of the Chronic Research Disease
Group, an interdisciplinary biomedical research group committed to
the investigation of chronic illnesses to improve public health,
and as part of this, served as the coordinating center for the
United States Renal Data System (USRDS) and its Annual Data Report
from 2000 through 2014. Dr. Collins was presented the
Distinguished Service Award by the National Kidney Foundation (NKF)
in 2003, and served as the President of the NKF from 2006 through
2008. He has over 200 clinical publications, and is an
invited lecturer worldwide. Dr. Collins continues his
clinical practice with dialysis patients under his care as the
Medical Director for the DaVita Coon Valley Dialysis Unit.
Dr. Collins has served as a member of the NxStage® Scientific
Advisory Board for the last 4 years.
"I believe fresh approaches with innovative technologies are
essential to address the long intractable problems we've seen with
chronic dialysis therapy, particularly cardiovascular issues and
low quality of life," said Collins. "The talented NxStage team has
substantially advanced home dialysis therapies to date, and will
continue to do so on a broader scale with future innovations.
It will be a pleasure to help advance the care of the dialysis
population by advising NxStage on data-driven analytics and
communications while leading a world-class team of medical
advisors."
Dr. Collins will assume the leadership role from Dr.
Alan Hull, who has headed the
NxStage Medical Advisory Board since 2004.
"We have always actively sought the best scientific counsel in
our ongoing mission to invent, improve and inspire," said
Joe Turk, NxStage's President. "We
thank Dr. Hull for all of his years of commitment, and we are
delighted that Dr. Collins will now be collaborating so closely
with NxStage going forward. NxStage, and future patients for
our life-changing technologies, will benefit from the ongoing
contributions of Dr. Collins' tremendous knowledge and leadership
skills."
About NxStage Medical
NxStage Medical,
Inc. (Nasdaq: NXTM) is a medical device company, headquartered
in Lawrence, Massachusetts,
USA, that develops, manufactures and markets innovative
products for the treatment of ESRD and acute kidney failure. For
more information on NxStage and its products, please visit the
Company's website at www.nxstage.com.
Forward-Looking Statements
This release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this release that are not clearly historical in nature are
forward-looking, and the words "anticipate," "believe," "expect,"
"estimate," "plan," and similar expressions are generally intended
to identify forward-looking statements. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors including those that are
discussed in NxStage's filings with the Securities and
Exchange Commission, including the Quarterly Report on Form 10-Q
for the quarter ended June 30, 2014. NxStage is under no
obligation to (and expressly disclaims any such obligation to)
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
Media contact:
Meredith D'Agostino
mdagostino@451marketing.com
516-884-7162
Logo -
http://photos.prnewswire.com/prnh/20110503/MM94799LOGO
SOURCE NxStage Medical Inc.